<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974854</url>
  </required_header>
  <id_info>
    <org_study_id>P/2018/395</org_study_id>
    <nct_id>NCT03974854</nct_id>
  </id_info>
  <brief_title>Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>ALIX</acronym>
  <official_title>Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Metastatic Pancreatic Adenocarcinoma (ALIX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC)
      is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin,
      irinotecan, and oxaliplatin). Due to more hematologic (neutropenia) and gastrointestinal
      toxicities, FOLFIRINOX is only administered in fit patients (age &lt; 75 years, ECOG Performance
      status 0-1, and bilirubin &lt; 1.5 ULN).

      However, elderly or frail patients represent more than half of patients with PDAC and are
      treated with gemcitabine monochemotherapy. Maintaining more than one drug (polychemotherapy)
      may improve survival and quality of life in this population.

      ALIX is a non-comparative randomized 2:1 phase II study. This study will assess the efficacy
      and safety of the polychemotherapy with XELOXIRI-3 versus gemcitabine as first-line
      chemotherapy in elderly or frail patients with metastatic PDAC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months Progression-Free Survival (PFS) rate</measure>
    <time_frame>6 months after the date of initiation of treatment (1st day of 1st cycle of chemotherapy)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: XELOXIRI-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg / m2 on D1, D8 and D15, every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOXIRI-3</intervention_name>
    <description>chemotherapy with XELOXIRI-3 regimen</description>
    <arm_group_label>Arm A: XELOXIRI-3</arm_group_label>
    <other_name>Capecitabine</other_name>
    <other_name>Oxaliplatine</other_name>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>chemotherapy with Gemcitabine regimen</description>
    <arm_group_label>Arm B: Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria :

          -  Histologically proven pancreatic ductal adenocarcinoma

          -  Metastatic disease

          -  Measurable disease according to RECIST v1.1 criteria

          -  Age ≥ 75 years;

        OR age between 65 and 75 years AND with at least one frailty contraindication to the
        administration of chemotherapy with FOLFIRINOX:

          -  Eastern Cooperative Oncology Group Performance status (ECOG-PS) 2

          -  Total serum bilirubin &gt; 1.5 ULN (biliary drainage allowed)

          -  Clinico-biological frailty criteria:

          -  weight loss &gt; 10% in 6 months or &gt; 5% in 1 month

          -  or body mass index (BMI) ≤ 21

          -  or serum albumin &lt; 30 g/L

          -  or ADL (Activities of Daily Living) score &lt; 6

               -  Eligible for gemcitabine as first-line chemotherapy

               -  Registration in a national health care system

               -  Written informed consent obtained from the patient prior to performing any
                  protocol-related procedures

        Main Exclusion Criteria:

          -  Age &lt; 65 years

          -  Localized or locally advanced non-metastatic cancer

          -  ECOG-PS 3-4

          -  Previous treatment For advanced stage (locally advanced or metastatic): chemotherapy,
             radiochemotherapy; For localized stage: FOLFIRINOX chemotherapy (neoadjuvant or
             adjuvant); adjuvant chemotherapy with gemcitabine before relapse is permitted (provide
             it has been administered more than 6 months before)

          -  Uncontrolled intercurrent cardiovascular disease

          -  Known or suspected allergy or hypersensitivity to any of the study drugs
             (capecitabine, oxaliplatin, irinotecan, gemcitabine)

          -  Bowel obstruction or sub-obstruction or impossible oral treatment

          -  Prior peripheral neuropathy of grade ≥ 2

          -  Known complete dihydropyrimidine dehydrogenase (DPD) or UDP-glycosyltransferase 1
             polypeptide A1 (UGT1A1) deficiency

          -  Inadequate hematological, hepatic, and renal functions

          -  Psychiatric illness/social situations that would limit compliance with study
             requirement, substantially increase risk of incurring AEs (Adverse Events) or
             compromise the ability of the patient to give written informed consent

          -  Tutelage or guardianship

          -  Diagnosis of any second malignancy within the last 2 years, except for adequately
             treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix
             uteri

          -  Current participation in another clinical trial using therapeutic experimental agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angélique VIENOT, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angélique Dr VIENOT</last_name>
    <phone>+33381479999</phone>
    <email>a3vienot@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion JACQUIN</last_name>
    <email>m1jacquin@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique VIENOT</last_name>
    </contact>
    <investigator>
      <last_name>Angélique VIENOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelique VIENOT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BORG, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

